CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia will be presented in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6 – 9, 2026. Abstract Title: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b Trial Session Type: Late-Breaking Science (Oral Presentation) Session Title: LBS.05 New Frontiers in Cardiometabolic Risk Reduction Session Date and Time: Monday, November 9, 2026, 8:00 a.m.

GlobeNewsWire • 4 hours ago

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $54, representing a -5.82% change from its previous close.

Zacks Investment Research • Oct 6, 2026

3 Trending Names Overtaking Wall Street Today

Wall Street is buzzing today thanks to an overdue reprieve from bond yields.

Schaeffers Research • Oct 6, 2026

Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks Investment Research • Oct 5, 2026

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company's Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.

GlobeNewsWire • Oct 2, 2026

CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them?

CRISPR Therapeutics has two important data readouts coming up soon. In both cases, it'll need to demonstrate that its candidate is more effective than the alternatives in development and on the market.

The Motley Fool • Sep 29, 2026

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Investment Research • Sep 29, 2026

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why

CRISPR Therapeutics AG (CRSP) reached $54.23 at the closing of the latest trading day, reflecting a -2.64% change compared to its last close.

Zacks Investment Research • Sep 25, 2026

CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

CRISPR Therapeutics is transitioning into a commercial-stage company with its pioneering gene-editing treatment, CASGEVY. Vertex Pharmaceuticals maintains a dominant, highly profitable position in the global cystic fibrosis market.

The Motley Fool • Sep 24, 2026

Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing

CRISPR Therapeutics AG remains a long-term Buy, anchored by Casgevy's commercial success and management's execution in ex vivo gene editing. Casgevy's Q2 sales grew 78% sequentially, reinforcing its blockbuster potential despite market skepticism and slow initial uptake. Anthropic's AI-driven gene editing discovery introduces potential competitive and funding risks, but clinical impact appears distant.

Seeking Alpha • Sep 24, 2026